Gregory Stewart
Urology · Murfreesboro, TNNPI 1487888558
Payments from drug & device makers
Across 289 payments — averaging $19.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$977
- Astellas Pharma US Inc$696
- Boston Scientific$538
- Johnson & Johnson$464
- Sumitomo Pharma America, Inc.$427
- Rochester Medical Corporation$326
- plus $2K from 30 others
What the payments were for
- Food & beverage$5,40197%
- Education$1943%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 59 | $977 |
| Astellas Pharma US Inc | 40 | $696 |
| Boston Scientific | 30 | $538 |
| Johnson & Johnson | 17 | $464 |
| Sumitomo Pharma America, Inc. | 21 | $427 |
| Rochester Medical Corporation | 15 | $326 |
| Urogen Pharma, Inc. | 13 | $254 |
| Endo Pharmaceuticals Inc. | 16 | $218 |
| Urovant Sciences Inc | 11 | $214 |
| Laborie Medical Technologies Corp. | 5 | $149 |
| Procept Biorobotics Corporation | 3 | $149 |
| Coloplast | 7 | $129 |
| Medtronic | 4 | $85 |
| Myovant Sciences Inc. | 6 | $85 |
| Tolmar, Inc. | 3 | $78 |
| Stryker | 2 | $76 |
| 180 Medical, Inc. | 3 | $70 |
| Mission Pharmacal Company | 3 | $56 |
| Valencia Technologies Corporation | 2 | $56 |
| Progenics Pharmaceuticals, Inc. | 3 | $54 |
| EDAP Technomed Inc | 3 | $54 |
| Ferring Pharmaceuticals Inc. | 3 | $51 |
| Clarus Therapeutics Inc. | 3 | $47 |
| Olympus America Inc. | 2 | $45 |
| Accord Healthcare, Inc. | 2 | $42 |
| Bayer | 2 | $34 |
| Endo USA, Inc. | 1 | $31 |
| Axonics, Inc. | 2 | $26 |
| Antares Pharma, Inc. | 1 | $25 |
| Dendreon Pharmaceuticals LLC | 1 | $25 |
| Blue Earth Diagnostics | 1 | $21 |
| C. R. Bard, Inc. & Subsidiaries | 1 | $21 |
| Travere Therapeutics, Inc. | 1 | $21 |
| ABC Home Medical Supply, Inc. | 1 | $19 |
| Kowa Pharmaceuticals America, Inc. | 1 | $15 |
| Tolmar Pharmaceuticals, Inc. | 1 | $15 |
How this compares
$5,595 in reported general payments places this provider in the 60th percentile of 276 urology providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GemtesaVibegron | 136 | $81,104 |
| MyrbetriqMirabegron | 119 | $70,770 |
| Tamsulosin Hcl | 768 | $11,507 |
| Silodosin | 82 | $7,116 |
| Solifenacin Succinate | 43 | $5,748 |
| Finasteride | 414 | $5,547 |
| Potassium Citrate ErPotassium Citrate | 23 | $2,760 |
| Trimethoprim | 47 | $2,662 |
| Trospium Chloride | 25 | $1,973 |
| Oxybutynin Chloride ErOxybutynin Chloride | 87 | $1,967 |
| Methenamine Hippurate | 28 | $1,816 |
| Estradiol | 26 | $1,457 |
| Tolterodine Tartrate ErTolterodine Tartrate | 13 | $1,251 |
| Cephalexin | 60 | $714 |
| NitrofurantoinNitrofurantoin Macrocrystal | 18 | $442 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Sumitomo Pharma America, Inc.Gemtesa | $427 | $81,104136 claims |
| Astellas Pharma US IncMyrbetriq | $696 | $70,770119 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 276 urology providers in Tennessee.
Other urology in Murfreesboro
- Gautam JayramNashville$16.1M
- David MorrisHendersonville$7.3M
- David PensonNashville$4.4M
- L KnollNashville$2.1M
- David GubinMemphis$1M
- Paul EberGermantown$795K
- Roger DmochowskiNashville$792K
- Melissa KaufmanNashville$617K
- Amy LuckenbaughNashville$547K
- Adam StewartGermantown$487K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.